NBIX - NEUROCRINE BIOSCIENCES INC

128.13
-1.510   -1.178%

Share volume: 903,600
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$129.64
-1.51
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 38%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.21%
1 Month
-8.19%
3 Months
-17.33%
6 Months
-10.90%
1 Year
13.35%
2 Year
-5.32%
Key data
Stock price
$128.13
P/E Ratio 
29.55
DAY RANGE
$126.95 - $129.25
EPS 
$4.81
52 WEEK RANGE
$84.23 - $160.18
52 WEEK CHANGE
$15.57
MARKET CAP 
14.141 B
YIELD 
N/A
SHARES OUTSTANDING 
100.363 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-30-2025
BETA 
0.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,104,022
AVERAGE 30 VOLUME 
$1,345,333
Company detail
CEO: Kevin C. Gorman
Region: US
Website: neurocrine.com
Employees: 1,200
IPO year: 1996
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.

Recent news